Author pages are created from data sourced from our academic publisher partnerships and public sources.
Pharmacokinetics of Single‐Dose Telmisartan 120 mg Given during and between Hemodialysis in Subjects with Severe Renal Insufficiency: Comparison with Healthy Volunteers
The pharmacokinetics of oral telmisartan 120 mg evaluated in subjects with severe renal insufficiency between dialyses and during hemodialysis were compared with those observed in healthy male… Expand
Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
The duration of action and the pharmacokinetics of gliquidone (1-cyclohexyl-3-[[4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1, 3-dioxo-2(1H)-isochinolyl)ethyl]phenyl]-sulfonyl]-urea, AR-DF 26 SE, CAS… Expand
Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo.
- T. Mueller, C. Su, H. Weisenberger, R. Brickl, G. Nehmiz, W. Eisert
- British journal of clinical pharmacology
- 1 August 1990
1. In a randomized, double-blind trial we compared the inhibition of the platelet-vessel wall interactions in whole blood ex vivo. There were four groups of 24 healthy volunteers each of whom were… Expand
Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.
- T. Mueller, H. Weisenberger, R. Brickl, H. Narjes, F. Himmelsbach, J. Krause
- 19 August 1997
BACKGROUND Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute thrombotic events. Orally active GP IIb/IIIa antagonists are essential to… Expand
Dipyridamole Bioavailability in Subjects With Reduced Gastric Acidity
- H. Derendorf, C. Vandermaelen, R. Brickl, Tom R MacGregor, W. Eisert
- Chemistry, Medicine
- Journal of clinical pharmacology
- 1 July 2005
Dipyridamole (DP) is an antiplatelet agent that shows decreased oral bioavailability with increased gastric pH that occurs with commonly prescribed antacids. An extended‐release (ER) formulation of… Expand
Pharmacokinetics and pharmacodynamics of psoralens after oral administration: considerations and conclusions.
We discovered a strong but saturable first-pass effect after oral administration of psoralens by using different doses and simultaneous or timed application of stable isotopes. Therefore, small… Expand
Clinical pharmacology of oral psoralen drugs.
Proper oral PUVA therapy includes the application of a psoralen drug and the administration of light, and both of these have to be adjusted to each other in regard to dose and timing. As psoralens… Expand
PK/PD simulations as a tool for rational design of clinical dosage regimens: an example with Fradafiban.
- R. Brickl, G. Heinzel, H. Weisenberger, H. Schubert, W. Rutsch, W. Roth
- International journal of clinical pharmacology…
- 1 October 1997
In clinical studies, pharmacodynamic effects should be achieved, e.g. maintenance of certain effects with reversibly acting drugs. Available data base for early phase II studies is frequently… Expand
Inhibition of Platelet Aggregation as a Surrogate Marker
- H. Narjes, T. H. Mueller, H. Weisenberger, B. Guth, R. Brickl
- Journal of clinical pharmacology
- 1 January 1997
Using acetylsalicylic acid—dipyridamole, a combined thromboxane receptor antagonist—thromboxane synthase inhibitor, and a fibrinogen receptor antagonist as examples, this article discusses the… Expand
Toxicity of 8-methoxypsoralen in cynomolgous monkeys (Macaca fascicularis).
Male and female cynomolgous monkeys were administered 0, 2, 6 or 18 mg/kg 8-methoxypsoralen (8-MOP) 3 times a week orally for 26 consecutive weeks. Dose-dependent emesis was the most sensitive… Expand